Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maxcyte (MXCT) Cash from Investing Activities (2020 - 2025)

Historic Cash from Investing Activities for Maxcyte (MXCT) over the last 6 years, with Q3 2025 value amounting to $5.2 million.

  • Maxcyte's Cash from Investing Activities rose 4390.24% to $5.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $14.6 million, marking a year-over-year increase of 22736.65%. This contributed to the annual value of $6.9 million for FY2024, which is 8739.27% down from last year.
  • Maxcyte's Cash from Investing Activities amounted to $5.2 million in Q3 2025, which was up 4390.24% from $1.5 million recorded in Q2 2025.
  • Maxcyte's 5-year Cash from Investing Activities high stood at $194.8 million for Q1 2022, and its period low was -$162.3 million during Q3 2021.
  • Over the past 5 years, Maxcyte's median Cash from Investing Activities value was $1.5 million (recorded in 2025), while the average stood at -$7.5 million.
  • In the last 5 years, Maxcyte's Cash from Investing Activities tumbled by 293960.94% in 2021 and then surged by 114141.41% in 2022.
  • Quarter analysis of 5 years shows Maxcyte's Cash from Investing Activities stood at -$11.4 million in 2021, then tumbled by 136.88% to -$27.1 million in 2022, then soared by 84.72% to -$4.1 million in 2023, then soared by 59.77% to -$1.7 million in 2024, then soared by 411.83% to $5.2 million in 2025.
  • Its Cash from Investing Activities was $5.2 million in Q3 2025, compared to $1.5 million in Q2 2025 and $9.5 million in Q1 2025.